Optinose

Description

• OptiNose is a biotech company that uses a breakthrough Exhalation Delivery System (EDS) to achieve high and deep nasal drug delivery. Reorganized in 2010 in order to develop and commercialize new products, OptiNose currently has offices in the US (Headquarters), Norway, and UK. Using the novel EDS technology, OptiNose has already successfully completed development of its first product, receiving FDA approval in 2016. Onzetra Xsail is for the treatment of Migraine and North American commercialization rights have been licensed to Avanir Pharmaceuticals (part of Otsuka).OptiNose's second product, OPN-375, is a potential blockbuster poised to become a standard of care treatment for tens of millions of people suffering from chronic nasal inflammatory diseases. The product has already successfully completed Phase III trials for its first indication.OptiNose delivery technology reproducibly and reliably delivers medication (large molecule, small molecule, or vaccine) to high and deep target regions inside the nose while avoiding lung deposition. The simple-to-use systems unlock potential for significant benefits, including better local activity, better systemic bioavailability and pharmacodynamics, better vaccines, and nose-to-brain activity for treating neurologic and psychiatric disorders.Available in single and multi-use devices for delivering liquid and powder formulations, refined by human-factors engineering and protected by a strong patent estate, the OptiNose concept has been used successfully in an approved product and proven in multiple clinical trials, confirming advantages over traditional nasal sprays. OptiNose is currently developing additional pipeline products using the new technology, and also welcomes discussion of technology licenses for delivery of proprietary medications. Current investors in OptiNose include Avista Capital Partners, WFD Ventures LLC and Entrepreneurs Fund LP. For more information visit www.OptiNose.com.
• 

  Headquarters:1020 Stony Hill Road Suite 300, Yardley, Pennsylvania, United States

  More
• 

  Phone Number: +1 267-364-3500

• 

  Website: http://www.optinose.com/

• 

  Employees:211

• 

  Revenue:$50 - 100M

• 

  Legal Name:Optinose

• Optinose's Social Media

  
• Is this data correct?

• |  NAICS Code: 325412  |

  Show More